Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300
October 20 2022 - 6:59AM
Business Wire
- U.S. Patent No. 11,471,431 relates to the use of LP-300 to
increase the survival time of patients with cancers overexpressing
thioredoxin or glutaredoxin.
- The patent issuance extends commercial protection for uses of
LP-300 until late 2032, increasing the potential for future
partnering opportunities and the development of additional programs
in specific cancer indications.
- Lantern has multiple additional pending patent applications
relating to LP-300 and is continuing to file patent applications in
this area.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("A.I.") and machine learning (“M.L.”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that the United States Patent and
Trademark Office (USPTO) has issued U.S. Patent No. 11,471,431, for
Lantern’s drug candidate LP-300, which is in a Phase 2 clinical
trial, Harmonic™, for never-smokers with relapsed non-small cell
lung cancer (NSCLC).
The patent is directed to increasing the survival time of cancer
patients receiving LP-300 for cancers that are marked by
overexpression of the regulatory proteins thioredoxin (TRX) or
glutaredoxin (GRX) and/or exhibition of TRX- or GRX-mediated
resistance to one or more chemotherapeutic interventions. TRX and
GRX are commonly overexpressed in adenocarcinomas, a cancer subtype
of NSCLC, and can lead to increased tumor resistance to
chemotherapy. LP-300 can inhibit activity of TRX and GRX, restoring
the redox balance of cancer cells and improving their sensitivity
to chemotherapy.
“Developing a strong and evolving patent estate around our drug
candidates and technologies is an essential part of our business
strategy. LP-300 has the potential to improve the lives of many
cancer patient groups, including never-smokers with NSCLC,” said
Panna Sharma, Lantern President and CEO. “The issuance of this
patent demonstrates our ability to create unique cancer insights
that we can then translate into clinical practice. This has the
potential to add significant value for patients and investors
alike,” continued Sharma.
U.S. Patent No. 11,471,431 is the latest U.S. patent added to
LP-300’s patent portfolio. Lantern’s current patent estate for
LP-300 includes 43 patents, covering 8 patent families. The
strengthened patent estate relating to LP-300 will stimulate the
opportunity for future partnering discussions with biopharma
companies.
About LP-300:
LP-300 is a dithio-containing drug candidate that interferes
with the activity of cancer promoting proteins by modifying
cysteine residues and creating adducts. LP-300’s intended mechanism
of action is to work together with chemotherapy to strongly
interact with cancer-promoting proteins including TRX/GRX and
tyrosine kinases. In a previous multi-center Phase 3 clinical
trial, a subset of never smoker NSCLC patients who received LP-300
with chemotherapy showed increased overall and two-year survival of
91% and 125%, respectively, compared to patients who received
chemotherapy alone. In addition, LP-300 has been administered in
multiple clinical trials to more than 1,000 people and has been
generally well tolerated.
About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage
oncology-focused biopharmaceutical company leveraging its
proprietary RADR® A.I. and machine learning platform to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. Lantern is
currently developing four drug candidates and an ADC program across
nine disclosed tumor targets, including two phase 2 programs. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes.
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221019005401/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024